Comparative Evaluation of Renal Dosimetry in Lutetium-177 DOTATATE and PSMA Therapies (EANM 2026) - Sep 29, 2026 - Abstract #OP-640; Pres time: Oct 20, 2026; 09:45 AM - 11:15 AM; Location: Hall K; "Both therapies exhibit safe renal dosimetry profiles when individualized assessment is performed. The higher variability observed in PSMA therapy highlights the importance of patient-specific dosimetry for treatment planning and risk assessment. Implementation of routine dosimetric evaluation may enhance therapeutic optimization and improve clinical outcomes in radionuclide therapy."
Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Prostate Cancer • Solid Tumor
|
|
R. Mishra 1; A. Nazar 2; P. Pradhan 2; A. Kumar 2
|